靶向JAK-STAT信号通路治疗银屑病的研究进展

doi:10.35541/cjd.20200715

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (3): 273-278.doi: 10.35541/cjd.20200715

靶向JAK-STAT信号通路治疗银屑病的研究进展

何谐栗玉珍

哈尔滨医科大学附属第二医院皮肤科 150081

收稿日期:2020-07-14 修回日期:2021-02-02 发布日期:2023-03-06
通讯作者: 栗玉珍 E-mail:liyuzhenchina@126.com
基金资助:
国家自然科学基金（81773320）

Targeting the JAK-STAT signaling pathway in the treatment of psoriasis

He Xie, Li Yuzhen

Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China

Received:2020-07-14 Revised:2021-02-02 Published:2023-03-06
Contact: Li Yuzhen E-mail:liyuzhenchina@126.com
Supported by:
National Natural Science Foundation of China（81773320）

摘要/Abstract

摘要： 【摘要】银屑病的发生与Janus激酶（JAK）-信号转导及转录激活因子（STAT）通路密切相关，白细胞介素（IL）-23、IL-22、干扰素γ等多种细胞因子均可通过该通路传递信号，从而促进银屑病中角质形成细胞增殖及异常分化、炎症细胞浸润等病理过程，提示靶向该通路是治疗银屑病的新策略。近年来，小分子JAK抑制剂治疗银屑病显示出较好的疗效和安全性，而靶向STAT的药物正在开发阶段，为银屑病的治疗提供了更多选择。该文综述靶向JAK-STAT信号通路治疗银屑病的研究进展。

关键词: 银屑病, Janus激酶类, STAT转录因子类, 治疗, JAK-STAT信号通路, JAK抑制剂, STAT抑制剂

Abstract: 【Abstract】 The Janus kinase （JAK）-signal transducer and activator of transcription （STAT） signaling pathway is closely related to the occurrence of psoriasis. Various cytokines, including interleukin （IL）-23, IL-22, interferon （IFN）-γ , etc., can promote some key pathologic processes （such as the proliferation and abnormal differentiation of keratinocytes, and infiltration of inflammatory cells） via the JAK-STAT pathway in psoriasis, which suggests that targeting JAK-STAT pathway is a new strategy for the treatment of psoriasis. In recent years, small-molecule JAK inhibitors have shown good efficacy and safety in the treatment of psoriasis, and drugs targeting STAT pathway have been under development, which provide more treatment options for psoriasis. This review summarizes progress in drugs targeting JAK-STAT signaling pathway in the treatment of psoriasis.

Key words: Psoriasis, Janus kinases, STAT transcription factors, Therapy, JAK-STAT pathway, JAK inhibitors, STAT inhibitors

何谐栗玉珍. 靶向JAK-STAT信号通路治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023,56(3):273-278. doi:10.35541/cjd.20200715

He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.doi:10.35541/cjd.20200715

参考文献 54

［1］	Banerjee S, Biehl A, Gadina M, et al. JAK⁃STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects［J］. Drugs, 2017,77（5）:521⁃546. doi: 10.1007/s40265⁃017⁃0701⁃9.
［2］	Ciechanowicz P, Rakowska A, Sikora M, et al. JAK⁃inhibitors in dermatology: current evidence and future applications［J］. J Dermatolog Treat, 2019,30（7）:648⁃658. doi: 10.1080/09546634. 2018.1546043.
［3］	Chen M, Dai SM. A novel treatment for psoriatic arthritis: Janus kinase inhibitors［J］. Chin Med J （Engl）, 2020,133（8）:959⁃967.doi: 10.1097/CM9.0000000000000711.
［4］	Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases［J］. Nat Rev Drug Discov, 2017,16（12）:843⁃862. doi: 10.1038/nrd.2017.201.
［5］	Chalmin F, Humblin E, Ghiringhelli F, et al. Transcriptional programs underlying Cd4 T cell differentiation and functions［J］. Int Rev Cell Mol Biol, 2018,341:1⁃61. doi: 10.1016/bs.ircmb. 2018.07.002.
［6］	Long D, Chen Y, Wu H, et al. Clinical significance and immunobiology of IL⁃21 in autoimmunity［J］. J Autoimmun, 2019,99:1⁃14. doi: 10.1016/j.jaut.2019.01.013.
［7］	Yang L, Li B, Dang E, et al. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3［J］. J Dermatol Sci, 2016,81（2）:85⁃92. doi: 10.1016/j.jdermsci.2015.11.007.
［8］	Chen L, Shen Z. Tissue⁃resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders［J］. Cell Mol Immunol, 2020,17（1）:64⁃75. doi: 10. 1038/s41423⁃019⁃0291⁃4.
［9］	Deng Y, Wang Z, Chang C, et al. Th9 cells and IL⁃9 in autoimmune disorders: pathogenesis and therapeutic potentials［J］. Hum Immunol, 2017,78（2）:120⁃128. doi: 10.1016/j.humimm. 2016.12.010.
［10］	Morelli M, Scarponi C, Mercurio L, et al. Selective immunomodulation of inflammatory pathways in keratinocytes by the Janus kinase （JAK） inhibitor tofacitinib: implications for the employment of JAK⁃targeting drugs in psoriasis［J］. J Immunol Res, 2018,2018:7897263. doi: 10.1155/2018/7897263.
［11］	Johansen C, Rittig AH, Mose M, et al. STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes［J/OL］. PLoS One, 2017,12（5）:e0176994. doi: 10.1371/journal.pone.0176994.
［12］	Liu L, Wu Y, Cao K, et al. Shikonin inhibits IFN⁃γ⁃induced K17 over⁃expression of HaCaT cells by interfering with STAT3 signaling［J］. Int J Clin Exp Pathol, 2015,8（8）:9202⁃9207.
［13］	Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
［14］	Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis［J］. J Am Acad Dermatol, 2012,67（4）:658⁃664. doi: 10.1016/j.jaad.2011.12.018.
［15］	Krueger J, Clark JD, Suárez⁃Fariñas M, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study［J］. J Allergy Clin Immunol, 2016,137（4）:1079⁃1090. doi: 10.1016/j.jaci.2015.12.1318.
［16］	Abdulrahim H, Sharlala H, Adebajo AO. An evaluation of tofacitinib for the treatment of psoriatic arthritis［J］. Expert Opin Pharmacother, 2019,20（16）:1953⁃1960. doi: 10.1080/14656566. 2019.1657404.
［17］	Burmester GR, Curtis JR, Yun H, et al. An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long⁃term extension studies with comparison to real⁃world observational data［J］. Drug Saf, 2020,43（4）:379⁃392. doi: 10.1007/s40264⁃020⁃00904⁃9.
［18］	Strober BE, Gottlieb AB, van de Kerkhof P, et al. Benefit⁃risk profile of tofacitinib in patients with moderate⁃to⁃severe chronic plaque psoriasis: pooled analysis across six clinical trials［J］. Br J Dermatol, 2019,180（1）:67⁃75. doi: 10.1111/bjd.17149.
［19］	Zhang J, Tsai TF, Lee MG, et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: aphase 3, randomized, double⁃blind, placebo⁃controlled study［J］. J Dermatol Sci, 2017,88（1）:36⁃45. doi: 10. 1016/j.jdermsci.2017.05.004.
［20］	Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial［J］. BMC Dermatol, 2016,16（1）:15. doi: 10.1186/s12895⁃016⁃0051⁃4.
［21］	Kathuria H, Nguyen D, Handral HK, et al. Proposome for transdermal delivery of tofacitinib［J］. Int J Pharm, 2020,585:119558. doi: 10.1016/j.ijpharm.2020.119558.
［22］	Mössner R, Hoff P, Mohr J, et al. Successful therapy of palmoplantar pustulosis with tofacitinib⁃report on three cases［J］. Dermatol Ther, 2020,33（4）:e13753. doi: 10.1111/dth.13753.
［23］	Wang YA, Rosenbach M. Successful treatment of refractory tumor necrosis factor inhibitor⁃induced palmoplantar pustulosis with tofacitinib: report of case［J］. JAAD Case Rep, 2020,6（2）:115⁃118. doi: 10.1016/j.jdcr.2019.12.006.
［24］	Shibata T, Muto J, Hirano Y, et al. Palmoplantar pustulosis⁃like eruption following tofacitinib therapy for juvenile idiopathic arthritis［J］. JAAD Case Rep, 2019,5（6）:518⁃521. doi: 10.1016/j.jdcr.2019.03.024.
［25］	Koumaki D, Koumaki V, Lagoudaki E, et al. Palmoplantar pustulosis⁃like eruption induced by baricitinib for treatment of rheumatoid arthritis［J］. Eur J Case Rep Intern Med, 2020,7（1）:001383. doi: 10.12890/2019_001383.
［26］	Di Domizio J, Castagna J, Algros MP, et al. Baricitinib⁃induced paradoxical psoriasis［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:e391⁃e393. doi: 10.1111/jdv.16293.
［27］	Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF⁃06700841 in patients with plaque psoriasis: phase IIa, randomized, double⁃blind, placebo⁃controlled trial［J］. J Invest Dermatol, 2020,140（12）:2359⁃2370. doi: 10.1016/j.jid.2020.03. 962.
［28］	Works MG, Yin F, Yin CC, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod⁃induced psoriasis⁃like dermatitis by inhibiting IL⁃22 and the IL⁃23/IL⁃17 axis［J］. J Immunol, 2014,193（7）:3278⁃3287. doi: 10.4049/jimmunol.1400205.
［29］	Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double⁃blind, placebo⁃controlled, sequential dose⁃escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2015,173（3）:767⁃776. doi: 10.1111/bjd.13745.
［30］	Jones P, Storer RI, Sabnis YA, et al. Design and synthesis of a pan⁃Janus kinase inhibitor clinical candidate （PF⁃06263276） suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin［J］. J Med Chem, 2017,60（2）:767⁃786. doi: 10.1021/acs.jmedchem.6b01634.
［31］	Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE⁃052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents［J］. Exp Dermatol, 2018,27（1）:22⁃29. doi: 10.1111/exd.13370.
［32］	Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis （EQUATOR）: results from a randomised, placebo⁃controlled, phase 2 trial［J］. Lancet, 2018,392（10162）:2367⁃2377. doi: 10.1016/S0140⁃6736（18）32483⁃8.
［33］	Orbai AM, Ogdie A, Gossec L, et al. Effect of filgotinib on health⁃related quality of life in active psoriatic arthritis: a randomized phase 2 trial （EQUATOR）［J］. Rheumatology （Oxford）, 2020,59（7）:1495⁃1504. doi: 10.1093/rheumatology/kez408.
［34］	Bissonnette R, Luchi M, Fidelus⁃Gort R, et al. A randomized, double⁃blind, placebo⁃controlled, dose⁃escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis［J］. J Dermatolog Treat, 2016,27（4）:332⁃338. doi: 10.3109/09546634. 2015.1115819.
［35］	Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF⁃04965842 in patients with moderate⁃to⁃severe psoriasis: phase II, randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2018,179（1）:54⁃62. doi: 10.1111/bjd.16004.
［36］	Ludbrook VJ, Hicks KJ, Hanrott KE, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo⁃controlled phase IIa study［J］. Br J Dermatol, 2016,174（5）:985⁃995. doi: 10.1111/bjd.14399.
［37］	Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain［J］. Sci Transl Med, 2019,11（502）:eaaw1736. doi: 10.1126/scitranslmed.aaw1736.
［38］	Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis［J］. N Engl J Med, 2018,379（14）:1313⁃1321. doi: 10.1056/NEJMoa1806382.
［39］	Singh R, Pradhan V, Roberts ES, et al. Safety and pharmacokinetics of the oral TYK2 inhibitor PF⁃06826647: a phase I, randomized, double⁃blind, placebo⁃controlled, dose⁃escalation study［J/OL］. Clin Transl Sci, 2020［2021⁃02⁃02］.https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12929. doi: 10.1111/cts.12929.
［40］	Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA⁃21, a Stat3 inhibitor［J］. J Invest Dermatol, 2011,131（1）:108⁃117. doi: 10.1038/jid.2010.255.
［41］	Park JS, Kwok SK, Lim MA, et al. STA⁃21, a promising STAT⁃3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis［J］. Arthritis Rheumatol, 2014,66（4）:918⁃929. doi: 10.1002/art.38305.
［42］	Kim JY, Ahn J, Kim J, et al. Nanoparticle⁃assisted transcutaneous delivery of a signal transducer and activator of transcription 3⁃inhibiting peptide ameliorates psoriasis⁃like skin inflammation［J］. ACS Nano, 2018,12（7）:6904⁃6916. doi: 10. 1021/acsnano.8b02330.
［43］	Schöneberger H, Weiss A, Brill B, et al. The integration of a Stat3 specific peptide aptamer into the thioredoxin scaffold protein strongly enhances its inhibitory potency［J］. Horm Mol Biol Clin Investig, 2011,5（1）:1⁃9. doi: 10.1515/HMBCI.2011. 013.
［44］	Mack L, Brill B, Delis N, et al. Stat3 is activated in skin lesions by the local application of imiquimod, a ligand of TLR7, and inhibited by the recombinant peptide aptamer rS3⁃PA［J］. Horm Mol Biol Clin Investig, 2012,10（2）:265⁃272.doi: 10.1515/hmbci⁃2012⁃0007.
［45］	Miyoshi K, Takaishi M, Digiovanni J, et al. Attenuation of psoriasis⁃like skin lesion in a mouse model by topical treatment with indirubin and its derivative E804［J］. J Dermatol Sci, 2012,65（1）:70⁃72. doi: 10.1016/j.jdermsci.2011.10.001.
［46］	Tang L, He S, Wang X, et al. Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3［J］. Exp Dermatol, 2018,27（3）:268⁃275. doi: 10.1111/exd.13511.
［47］	Skyvalidas DΝ, Mavropoulos A, Tsiogkas S, et al. Curcumin mediates attenuation of pro⁃inflammatory interferon γ and interleukin 17 cytokine responses in psoriatic disease, strengthening its role as a dietary immunosuppressant［J］. Nutr Res, 2020,75:95⁃108. doi: 10.1016/j.nutres.2020.01.005.
［48］	Marepally S, Boakye CH, Patel AR, et al. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic⁃like plaques［J］. Nanomedicine （Lond）, 2014,9（14）:2157⁃2174. doi: 10.2217/nnm.13.202.
［49］	Ran LW, Wang H, Lan D, et al. Effect of RNA interference targeting STAT3 gene combined with ultrasonic irradiation and SonoVue microbubbles on proliferation and apoptosis in keratinocytes of psoriatic lesions［J］. Chin Med J （Engl）, 2018,131（17）:2097⁃2104. doi: 10.4103/0366⁃6999.239297.
［50］	Ran LW, Wang H, Lan D, et al. Effects of RNA interference combined with ultrasonic irradiation and SonoVue microbubbles on expression of STAT3 gene in keratinocytes of psoriatic lesions［J］. J Huazhong Univ Sci Technolog Med Sci, 2017,37（2）:279⁃285. doi: 10.1007/s11596⁃017⁃1728⁃6.
［51］	Hu XP, Xie Q, Chen CF, et al. Let⁃7a inhibits T⁃cell proliferation and IFN⁃γ secretion by down⁃regulating STAT3 expression in patients with psoriasis［J］. Cell Physiol Biochem, 2017,42（1）:115⁃125. doi: 10.1159/000477120.
［52］	Chowdhari S, Saini N. hsa⁃miR⁃4516 mediated downregulation of STAT3/CDK6/UBE2N plays a role in PUVA induced apoptosis in keratinocytes［J］. J Cell Physiol, 2014,229（11）:1630⁃1638. doi: 10.1002/jcp.24608.
［53］	Wang Y, Yu X, Wang L, et al. miR⁃320b is down⁃regulated in psoriasis and modulates keratinocyte proliferation by targeting AKT3［J］. Inflammation, 2018,41（6）:2160⁃2170. doi: 10.1007/s10753⁃018⁃0859⁃7.
［54］	Yan JJ, Qiao M, Li RH, et al. Downregulation of miR⁃145⁃5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis［J］. Br J Dermatol, 2019,180（2）:365⁃372. doi: 10.1111/bjd.17256.

[1]	中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 0(4): 20220819-e20220819.
[2]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 0(4): 20230004-e20230004.
[3]	阮诗钒张鹏林婷婷罗仁炜鲍思怡薛晨瑶童泽群张亮亮龚婷纪超. 寻常型银屑病与血脂异常的相关性研究[J]. 中华皮肤科杂志, 2023, 0(3): 20220322-e20220322.
[4]	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识[J]. 中华皮肤科杂志, 2023, 56(3): 191-203.
[5]	周健俞晨王刚. 司库奇尤单抗治疗13例难治性局限性脓疱型银屑病的临床疗效与安全性观察[J]. 中华皮肤科杂志, 2023, 56(3): 247-251.
[6]	胡琨杨晶王巧林陈军臣张谧朱武张斌窦冠珅 Wendong Chen, 匡叶红. [开放获取] 依奇珠单抗治疗银屑病短期疗效的单中心病例回顾性研究[J]. 中华皮肤科杂志, 2023, 56(3): 210-215.
[7]	万立胡彬罗红玉方美珍韩丽娟陈强周小勇陈柳青陈金波. 天疱疮或大疱性类天疱疮合并单纯疱疹病毒感染8例临床特征及治疗分析[J]. 中华皮肤科杂志, 2023, 56(3): 229-233.
[8]	罗帅寒天龙海陆前进. 2022年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2023, 56(3): 266-269.
[9]	陈奇权杨显杰顾恒徐金华郝飞姚煦宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹专家诊治共识（2023）》[J]. 中华皮肤科杂志, 2023, 0(3): 20220814-e20220814.
[10]	苑辰闫言王宝玺. 反常性痤疮的生物治疗进展[J]. 中华皮肤科杂志, 2023, 56(3): 270-273.
[11]	张红燕李丽王明霞董银卯孟宏易帆. 益生菌在痤疮治疗中的应用进展[J]. 中华皮肤科杂志, 2023, 56(3): 283-285.
[12]	洪芷榆谢红付李吉黄莹雪. 发光二极管红黄光治疗急性发作期面部炎症性皮肤病的支付意愿分析[J]. 中华皮肤科杂志, 2023, 0(3): 20220128-e20220128.
[13]	任芬芬王鹏张景展康晓静. 基于网络药理学预测中药在抗卡波西肉瘤血管生成治疗中的潜在有效成分及分子作用机制[J]. 中华皮肤科杂志, 2023, 0(3): 20220140-e20220140.
[14]	王召阳向欣陈云刘苗朝阳赵欣荣张振华刘元香马琳徐子刚. 生物制剂与甲氨蝶呤治疗儿童重度斑块状银屑病疗效及安全性比较[J]. 中华皮肤科杂志, 2023, 56(2): 112-117.
[15]	贾元源毛秋雨杨婧怡闵玮. 度普利尤单抗治疗中重度老年特应性皮炎临床疗效观察[J]. 中华皮肤科杂志, 2023, 56(2): 125-129.

靶向JAK-STAT信号通路治疗银屑病的研究进展

Targeting the JAK-STAT signaling pathway in the treatment of psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 54

相关文章 15

Metrics

本文评价

推荐阅读 10